Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -19083.66% is 91% above its 4-year average of -220161.38%, near the high end of its 4-year range (-1294600.00%–9792.55%).
97.06% above its 12-month average of -649394.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2020 (2020-12-31): -1294600.00%.
EBITDA MARGIN
-19083.66%
EBITDA MARGIN AVG TTM
-649394.14%
EBITDA MARGIN AVG 3Y
-429665.24%
EBITDA MARGIN AVG 5Y
-220161.38%
EBITDA MARGIN AVG 10Y
-188904.57%
EBITDA MARGIN AVG 15Y
-2624.02%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.06%
CURRENT VS 3Y AVG
+95.56%
CURRENT VS 5Y AVG
+91.33%
CURRENT VS 10Y AVG
+89.90%
CURRENT VS 15Y AVG
-627.27%
CURRENT VS 20Y AVG
N/A
Savara Inc.
Market Cap
$954.96M
EBITDA Margin
-19083.66%
TTM Avg
-649394.14%
3Y Avg
-429665.24%
5Y Avg
-220161.38%
Market Cap
$941.60M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$969.98M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
Market Cap
$938.35M
EBITDA Margin
-448.41%
TTM Avg
-402.69%
3Y Avg
-402.69%
5Y Avg
-402.69%
Market Cap
$935.90M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$977.87M
EBITDA Margin
17.12%
TTM Avg
8.95%
3Y Avg
16.20%
5Y Avg
17.02%
Market Cap
$930.32M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.62M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$986.61M
EBITDA Margin
-31.64%
TTM Avg
-36.17%
3Y Avg
-63.38%
5Y Avg
-163.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $954.96M | -19083.66% | -649394.14% | -429665.24% | -220161.38% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $941.60M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | -448.41% | -402.69% | -402.69% | -402.69% |
| CeriBell, Inc. (CBLL)vs › | $935.90M | -64.07% | -61.50% | -81.15% | -81.15% |
| Pacira BioSciences, Inc. (PCRX)vs › | $977.87M | 17.12% | 8.95% | 16.20% | 17.02% |
| MoonLake Immunotherapeutics (MLTX)vs › | $930.32M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $986.61M | -31.64% | -36.17% | -63.38% | -163.90% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.02M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-19083.7%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-12-31 | -1294600.00% |
| 2020-09-30 | -4188.28% |
| 2017-12-31 | 9792.55% |
| 2017-03-31 | -6048.94% |
| 2016-12-31 | -9974.70% |
| 2016-09-30 | -15948.89% |
| 2010-12-31 | -1363.77% |
| 2009-09-30 | -779.17% |
| 2009-06-30 | -842.22% |
| 2009-03-31 | -1042.18% |
| 2008-12-31 | -1498.60% |
| 2008-06-30 | -1329.42% |
| 2007-03-31 | -1138.82% |
| 2005-12-31 | -658.11% |
